A Phase II Study of Rucaparib to Treat Metastatic Prostate Cancer


Full Title

CO-338-052: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency


PARP is a protein that helps cells, including cancer cells, repair their DNA. Some cancer cells, especially those that have mutations in genes like BRCA and ATM, may rely on the PARP protein to repair their DNA and survive. If the PARP protein is blocked, these cells may die.

Rucaparib is a PARP inhibitor used to treat ovarian cancer. In this study, researchers are evaluating rucaparib to treat metastatic prostate cancer that has continued to grow despite hormonal therapy (“castration-resistant prostate cancer”). Rucaparib is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have metastatic castration-resistant prostate cancer that has continued to grow despite therapy, including hormonal therapy and chemotherapy.
  • Patients must have a mutation in a DNA repair gene, such as BRCA or ATM
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for men age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Wassim Abida at 646-422-4633.